Managing Partner & CEO
Alexey is a co-founder and holds leadership position at Unicorn Capital Partners since its inception in December 2019. Previously, in 2017-2019, served as head of Pharmstandard ventures (venture arm of Russia’s leading pharmaceutical company), and as a managing partner at its predecessor company, Inbio ventures (2013-2017). From 2010 to 2013 Alexey was a part of Bioprocess capital investment team, which was Russia’s first biotech-focused venture fund.
Some of his recent Board of Director appointments include: Aquinox pharmaceuticals (Series C, IPO NASDAQ: AQXP, exit on positive phase 2 data); Protagonist therapeutics (Series B, Series C, IPO NASDAQ, partnered with Janssen in >$1B transaction); Argos (lead investor in Series E, IPO NASDAQ); Allena (Series B, Series C, IPO NASDAQ); Avelas biosciences (lead investor in Series C); TearSolutions (lead investor in Series B). 8 out of 11 investments went public on NASDAQ. Some of the valuable syndication partners included Third Rock Ventures, JJDC, Frazier, Bessemer, Forbion, Pfizer ventures, HBM, TVM, Avalon.
Alexey graduated as MS (1995) and then as PhD in biochemistry (2000) from Moscow State University; 2000-2002 – postdoctoral fellow at the lab of biomolecular sciences, Wageningen University, the Netherlands.